Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced lung cancer: drug cocktails under trial

NCT ID NCT06996782

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests new combinations of cancer drugs in people with advanced or metastatic non-small cell lung cancer. The goal is to find safer and more effective treatments. About 152 participants will receive either novel drug pairs or new drugs plus standard therapy. The study focuses on safety, side effects, and whether tumors shrink.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 152 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with confirmed squamous or non-squamous NSCLC with a current Stage IV mNSCLC. * Provision of acceptable archival tumour tissue (or fresh tumour tissue biopsy if archival tumour tissue is not available and if clinically feasible) is mandatory at screening. * Measurable disease as defined by at least one lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter. * Minimum life expectancy of 12 weeks in the opinion of the investigator. * Adequate organ and marrow function. * Contraceptive use by male or female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Adequate organ and marrow function. Inclusion Criteria for Sub Study 2: * Programmed death-ligand 1 (PD-L1) tumour proportion score (TPS) ≥ 1% (per local report). * Adequate coagulation and urinalysis. * Minimum body weight of 30 kg. Exclusion Criteria: * Participants with epidermal growth factor receptor mutations, anaplastic lymphoma receptor fusions or any other known genomic alteration for which targeted therapy is approved in the first line per local standard of care. * Presence of small cell and neuroendocrine histology components. * Any severe or uncontrolled systemic diseases, including uncontrolled hypertension, and active bleeding diseases, ongoing or active known infection; interstitial lung disease/pneumonitis (of any grade); unstable and/or symptomatic venous thromboembolism, serious chronic gastrointestinal conditions associated with diarrhoea, active non-infectious skin disease or substance abuse. * Has had a prior stem cell, bone marrow, allogenic tissue, or solid organ transplant. * Has an active autoimmune disease that has required systemic treatment in the past 5 years. * History of clinically significant arrhythmia, cardiomyopathy of any aetiology or symptomatic congestive heart failure. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention or presence of small cell and neuroendocrine histology components. * Persistent toxicities (common terminology criteria for adverse events \[CTCAE\] ≥ Grade 2) caused by previous anti-cancer therapy, excluding alopecia. * Spinal cord compression or symptomatic brain metastases. * Treatment with any other anti-cancer agents or immunosuppressive medication. * Palliative radiotherapy with a limited field of radiation within 2 weeks or with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks, prior to the first dose of study intervention. Exclusion Criteria for Sub Study 2: * Known active hepatitis A. * Acute hepatitis B infection (anti-hepatitis B core antibody \[HBc\] immunoglobulin M \[IgM\] positive) or chronic hepatitis B infection with HBV DNA ≥ 2000 IU/mL. * Active hepatitis C infection (anti-HCV positive with HCV RNA detectable) or anti- HCV positive with HCV RNA undetectable for less than 12 weeks following treatment for HCV. * Known human immunodeficiency virus (HIV) infection that is not well controlled. * Evidence of Grade ≥ 1 central nervous system (CNS) haemorrhage. * Uncontrolled arterial hypertension ≥ 150 mm Hg (systolic) and/or ≥ 100 mm Hg (diastolic). * Has radiologically documented evidence of major blood vessel invasion or encasement by cancer, or major airway invasion by cancer or intra-tumour cavitation. * Has experienced any arterial thrombotic event, a Grade ≥ 3 bleeding event or has gross haemoptysis. * Has significant bleeding disorders, serious or nonhealing wound, ulcer or clinically relevant congestive heart failure. * Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection. * Has cirrhosis at a level of Child-Pugh B (or worse), or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. * Prior systemic therapy received for advanced or mNSCLC. * Prior exposure to an anti-T-cell immunoreceptor with Ig and Immunoreceptor Tyrosine-based Inhibition Motif domains (TIGIT) therapy or immune-oncology agent such as anti-programmed cell death protein 1 (PD-1), anti-PD-L1, or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), or any other anti-cancer therapy targeting immune-regulatory receptors or mechanisms. * Chronic therapy with antiplatelet agents. * Prior exposure to anti-vascular endothelial growth factor (VEGF) therapy. * Medical contraindication to protocol-specified platinum doublet regimens or ramucirumab. * Known allergy or hypersensitivity to rilvegostomig or any of the excipients of rilvegostomig, cisplatin, carboplatin, paclitaxel or nab-paclitaxel or pemetrexed or ramucirumab.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced or metastatic non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced or metastatic non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    94 sites in 18 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Research Site

    RECRUITING

    Santa Rosa, California, 95403, United States

  • Research Site

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Research Site

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • Research Site

    NOT_YET_RECRUITING

    Detroit, Michigan, 48202, United States

  • Research Site

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Research Site

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • Research Site

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • Research Site

    WITHDRAWN

    Providence, Rhode Island, 02906, United States

  • Research Site

    RECRUITING

    Tyler, Texas, 75708, United States

  • Research Site

    NOT_YET_RECRUITING

    Anderlecht, 1070, Belgium

  • Research Site

    NOT_YET_RECRUITING

    Hasselt, 3500, Belgium

  • Research Site

    NOT_YET_RECRUITING

    Leuven, 3000, Belgium

  • Research Site

    NOT_YET_RECRUITING

    Barretos, 14784-400, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Fortaleza, 60336-232, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Natal, 59075-740, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Pelotas, 096015-280, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Porto Alegre, 90035-903, Brazil

  • Research Site

    NOT_YET_RECRUITING

    São Paulo, 01246-000, Brazil

  • Research Site

    NOT_YET_RECRUITING

    São Paulo, 05651-901, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, 610041, China

  • Research Site

    NOT_YET_RECRUITING

    Chongqing, 400072, China

  • Research Site

    NOT_YET_RECRUITING

    Deyang, 618000, China

  • Research Site

    NOT_YET_RECRUITING

    Fuzhou, 350014, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510405, China

  • Research Site

    RECRUITING

    Jinan, 250013, China

  • Research Site

    RECRUITING

    Shanghai, 200433, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, 201114, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, 110015, China

  • Research Site

    NOT_YET_RECRUITING

    Shenzhen, 518116, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, 430022, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, 430060, China

  • Research Site

    NOT_YET_RECRUITING

    Bordeaux, 33076, France

  • Research Site

    NOT_YET_RECRUITING

    Dijon, 21079, France

  • Research Site

    NOT_YET_RECRUITING

    Limoges, 87000, France

  • Research Site

    NOT_YET_RECRUITING

    Marseille, 13015, France

  • Research Site

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • Research Site

    NOT_YET_RECRUITING

    Nice, 06189, France

  • Research Site

    NOT_YET_RECRUITING

    Paris, 75005, France

  • Research Site

    RECRUITING

    Batumi, 6010, Georgia

  • Research Site

    RECRUITING

    Tbilisi, 0112, Georgia

  • Research Site

    RECRUITING

    Tbilisi, 0114, Georgia

  • Research Site

    RECRUITING

    Tbilisi, 0144, Georgia

  • Research Site

    WITHDRAWN

    Tbilisi, 0186, Georgia

  • Research Site

    NOT_YET_RECRUITING

    München, 81675, Germany

  • Research Site

    WITHDRAWN

    Münster, 48149, Germany

  • Research Site

    WITHDRAWN

    Oldenburg, 26121, Germany

  • Research Site

    NOT_YET_RECRUITING

    Regensburg, 93053, Germany

  • Research Site

    NOT_YET_RECRUITING

    Würzburg, 97080, Germany

  • Research Site

    NOT_YET_RECRUITING

    Milan, 20141, Italy

  • Research Site

    NOT_YET_RECRUITING

    Milan, 20162, Italy

  • Research Site

    NOT_YET_RECRUITING

    Orbassano, 10043, Italy

  • Research Site

    NOT_YET_RECRUITING

    Pavia, 27100, Italy

  • Research Site

    NOT_YET_RECRUITING

    Roma, 00168, Italy

  • Research Site

    RECRUITING

    Bunkyō City, 113-8431, Japan

  • Research Site

    RECRUITING

    Bunkyō City, 113-8677, Japan

  • Research Site

    RECRUITING

    Kashiwa, 277-8577, Japan

  • Research Site

    RECRUITING

    Kurume-shi, 830-0011, Japan

  • Research Site

    RECRUITING

    Kyoto, 602-8566, Japan

  • Research Site

    RECRUITING

    Niigata, 951-8566, Japan

  • Research Site

    RECRUITING

    Shinjuku-ku, 162-8655, Japan

  • Research Site

    RECRUITING

    Toyoake-shi, 470-1192, Japan

  • Research Site

    RECRUITING

    Kuala Lumpur, 59100, Malaysia

  • Research Site

    RECRUITING

    Kuala Selangor, 62250, Malaysia

  • Research Site

    RECRUITING

    Kuching, 93586, Malaysia

  • Research Site

    RECRUITING

    Singapore, 329563, Malaysia

  • Research Site

    RECRUITING

    Chisinau, MD-2025, Moldova

  • Research Site

    NOT_YET_RECRUITING

    Amsterdam, 1066CX, Netherlands

  • Research Site

    NOT_YET_RECRUITING

    Groningen, 9713 GZ, Netherlands

  • Research Site

    NOT_YET_RECRUITING

    Leiden, 2333 ZA, Netherlands

  • Research Site

    WITHDRAWN

    Lima, 15036, Peru

  • Research Site

    NOT_YET_RECRUITING

    Koszalin, 75-581, Poland

  • Research Site

    NOT_YET_RECRUITING

    Lodz, 93-338, Poland

  • Research Site

    NOT_YET_RECRUITING

    Olsztyn, 10-357, Poland

  • Research Site

    WITHDRAWN

    Belgrade, 11000, Serbia

  • Research Site

    WITHDRAWN

    Kragujevac, 34000, Serbia

  • Research Site

    WITHDRAWN

    Niš, 18000, Serbia

  • Research Site

    RECRUITING

    Seongbuk-Gu, 2841, South Korea

  • Research Site

    RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    RECRUITING

    Seoul, 05505, South Korea

  • Research Site

    RECRUITING

    Seoul, 3722, South Korea

  • Research Site

    RECRUITING

    Seoul, 6351, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Barcelona, 08035, Spain

  • Research Site

    NOT_YET_RECRUITING

    Barcelona, 08036, Spain

  • Research Site

    NOT_YET_RECRUITING

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    NOT_YET_RECRUITING

    Madrid, 28034, Spain

  • Research Site

    NOT_YET_RECRUITING

    Madrid, 28041, Spain

  • Research Site

    NOT_YET_RECRUITING

    Pamplona, 31008, Spain

  • Research Site

    NOT_YET_RECRUITING

    Pozuelo de Alarcón, 28223, Spain

  • Research Site

    NOT_YET_RECRUITING

    Valencia, 46009, Spain

  • Research Site

    NOT_YET_RECRUITING

    Valencia, 46010, Spain

  • Research Site

    RECRUITING

    Taichung, 40201, Taiwan

  • Research Site

    RECRUITING

    Taipei, 110, Taiwan

  • Research Site

    RECRUITING

    Taipei, 11696, Taiwan

  • Research Site

    RECRUITING

    Bangkok, 10700, Thailand

  • Research Site

    RECRUITING

    Chanthaburi, 22000, Thailand

  • Research Site

    RECRUITING

    Hat Yai, 90110, Thailand

  • Research Site

    RECRUITING

    Khon Kaen, 40002, Thailand

  • Research Site

    RECRUITING

    Rachathewi, 10400, Thailand

  • Research Site

    RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Ankara, 6200, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Fatih, 34093, Turkey (Türkiye)

  • Research Site

    WITHDRAWN

    Istanbul, 34752, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.